Untitled

306 JP:
Strong Performance: Based on previous quarter’s results, the company's profits attributable to owners of the parent have already reached 100% of full-year guidance, indicating robust performance. Profit growth accelerated at customer segments in recent quarters, which we think indicates an improvement in core earnings momentum.
Improving Loan-Deposit Spread Improvement: In Japan, the loan-deposit spread (excluding loans to the government) improved by 6 basis points year-on-year in Q1-3, potentially indicating better profitability on lending activities.
Manageable Credit Risk: Credit costs were only at 63% of full-year guidance for Q1-3, and the NPL ratio improved from 1.51% at end-March to 1.40% at end-December, suggesting good credit risk management.
Strong Balance Sheet: Despite a decrease, unrealized gains on securities remained high at ¥1.85trn as of end-December, indicating a robust balance sheet position.


8316 JP:
Strong Financial Performance: Based on last quarter’s results, profits attributable to owners of the parent and consolidated net business profits have reached 98% and 90% of full-year guidance respectively, indicating robust performance.
Improving Core Earnings: Consolidated net business profits before provisioning rose by 21% year-on-year, with potential for further growth due to Bank of Japan policy rate changes.
Expanding Interest Margins: The loan-deposit spread in Japan improved by 10 basis points year-on-year, with a 4 basis point quarter-on-quarter improvement in Q3, suggesting increasing profitability.
Low Credit Risk: Credit costs remained low, with Q1-3 credit costs at only 61% of full-year guidance. The NPL ratio improved from 0.81% at end-March to 0.68% at end-December.
Strong Balance Sheet: End-December unrealized gains on securities were ¥3.22trn, with other available-for-sale securities in a net gain position of ¥1.09trn, indicating a healthy securities portfolio.
Proactive Management: The company is considering raising profit targets and implementing strategic initiatives that are bearing fruit earlier than expected.
Future Growth Potential: Expectations of sustained contributions to profit growth from various business segments and potential for exceeding medium-term plan targets.
Shareholder Focus: Management's proactive stance on improving shareholder returns and focus on ROE-driven capital allocation.


6301 JP:
Strong Asian Market Presence: Komatsu has high exposure to Asia ex-Japan and China, accounting for around 22% of total sales in FY2024, which is higher than other global construction machinery producers. 
Recovery in Southeast Asian Sales: After a temporary downturn, sales in Southeast Asia (primarily Indonesia) have returned to growth recently, which is expected to have a major positive impact on earnings. 
Ongoing Price Effects: The company continues to benefit from price hikes, with the effect still higher than sector peers. Recent price increases for general construction machinery in Western markets are expected to boost profits into FY26.
Forex Benefit: A weaker yen is generally expected to benefit the Japanese exporters like Komatsu.
Resilience to Tariffs: While tariffs may affect earnings, the company's ability to pass on cost increases is expected to mitigate major negative impacts.
Attractive Valuation: The target price is based on a P/E of around 10x for FY27 EPS forecast, which could be considered reasonable for a company with Komatsu's market position and growth prospects.


9101 JP:
Improved Guidance: Management raised its full-year FY25 guidance for recurring profits, profits attributable to owners of the parent, and dividend per share (DPS from ¥260 to ¥310), indicating strong performance. Assuming a DPS of ¥300 in both 25/3 and 26/3, plus a potential share buyback of ¥150bn, the total shareholder return yield could exceed 10%.
Strong Air Cargo Performance: Nippon Yusen raised its full-year operating profit guidance for the air cargo transportation segment, despite the planned removal of Nippon Cargo Airlines from consolidated accounts.
Attractive Valuation: The stock is trading below book value while offering high shareholder returns.
Robust Profitability: Analysts forecast FY26 ROE of 8.5%, expecting profits to be higher than before, even assuming the resumption of shipping through the Red Sea. There's potential for profits to beat forecasts if the resumption of shipping through the Red Sea is delayed.
Strong Performance of ONE: Ocean Network Express (ONE), in which Nippon Yusen has a 38% stake, is performing well, with Q3 net profits ahead of guidance.
Medium-Term Plan Progress: The company is ahead of profit assumptions in its medium-term business plan, which could lead to a more favorable market view of its ability to generate high profits and shareholder returns.


1605 JP:
Strong FY24 Performance: Inpex generated profits attributable to owners of the parent of ¥427.3bn (up 33% y-y), outperforming both consensus forecasts.
Enhanced Shareholder Returns: Inpex announced a progressive dividend policy starting at ¥90 per share and increased the total shareholder return ratio to at least 50%, up from the previous 40%.
Ambitious Medium-Term Plan: The company aims for cumulative operating cash flow of at least ¥2.2trn over three years (2025-2027).
Increased Investment: Inpex projects investment cash flow of over ¥1.8trn over the next three years, up from ¥1.1trn in the past three years, focusing on expanding natural gas, LNG, CCS, and hydrogen operations.
Diversification Efforts: Investments in CCS, hydrogen, and other technologies show the company's efforts to diversify.
Long-term Vision: The company released its Inpex Vision 2035, indicating a focus on long-term strategic planning.


4502 JP:
Positive Phase 3 Results: Rusfertide demonstrated superior efficacy compared to current treatments for polycythemia vera (PV) in the VERIFY study, with 76.9% of patients not requiring phlebotomy versus 32.9% for placebo. The positive Phase 3 results for rusfertide mark a significant step towards gaining FDA approval, with a filing planned for Oct-Dec 2025.
Strong Vyvanse Performance: Sales of ADHD treatment Vyvanse have been solid, outperforming expectations despite generic competition. Supply shortages of generic Vyvanse have limited the impact on Takeda's sales.
Raised Guidance: Management increased its full-year FY25 core operating profit guidance to ¥1.15trn from ¥105mn.
Share Buyback: The company announced a share buyback program of up to ¥100.0bn between February and May 2025.
Leadership Transition: CEO Christophe Weber will be succeeded by Julie Kim, current head of the US business unit, in June 2026, potentially bringing a renewed focus on the US market.
Growth Prospects: Management is expected to focus on Entyvio and immunoglobulin drugs, areas with good growth potential.
Pipeline Progress: Marked progress in the development of new drugs in latter stages of development is expected to mitigate the impact of patent expiries in 2025.


4503 JP:
Positive Label Change for Izervay: The FDA approved the removal of treatment duration restrictions for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration.
Early Approval: The label change was approved before the PDUFA date, allowing for proactive prescribing to new and waiting patients.
Reduced Risk of Impairment Charges: The swift approval may reduce the risk of further impairment charges related to Izervay.
Strong Market Position: Izervay maintains a 60% share of prescriptions for new patients and is considered safer than competing drugs.
Potential for Prescription Growth: The label change is expected to bring further growth in prescription numbers for Izervay.
Strong Q3 Performance: Astellas reported Q3 sales of ¥517.4bn, beating analyst forecasts by ¥48.7bn, primarily due to strong performance of Xtandi and mirabegron. Despite generic competition, mirabegron sales increased by ¥15.5bn quarter-on-quarter, surprising positively.
Core Operating Profit Growth: Q3 core operating profits of ¥114.4bn beat analyst forecasts by ¥16.8bn, driven by sharp sales growth.
Maintained Guidance: Management retained its full-year FY25 guidance, indicating confidence in the company's performance.
Pipeline Development: While the release of top-line results for zolbetuximab in pancreatic cancer has been delayed, the continuation of the study suggests potential for future development.
Market Adaptability: The company's ability to adjust to market conditions, as seen with the gross-to-net adjustments for mirabegron, demonstrates flexibility in its business strategy.


4183 JP:
Strategic Focus on ROIC: Management is considering withdrawing from businesses with no prospects for earnings improvement, even in growth areas, indicating a stronger focus on Return on Invested Capital (ROIC).
Growth in Life & Healthcare Solutions (L&HS): The company expects substantial improvements in core operating profits in this segment from FY24 through FY28.
Pesticide Market Expansion: Mitsui Chemicals has expanded sales locations for its pesticide Tenebenal in Asia and expects growth for flupyrimin, which is environmentally friendly.
Vision Care Business Growth: The company anticipates an average annual growth of around 6% in the high refractive index lens market, with a focus on increasing sales in China.
Medical Business Restructuring: The company aims to expand its distribution network in the medical business, focusing on areas of strength while considering withdrawal from underperforming segments.
Basic & Green Materials (B&GM) Improvement: Management expects core operating profits in this segment to increase by around ¥20bn from FY24 through FY28 through business restructuring.
Production Capacity Adjustments: Plans include reducing TDI and ethylene production capacity at the Chiba LLP, and moving to an asset-lite structure for overseas phenol operations.
Ethylene Facilities Optimization: The company is working on a grand design for optimizing its ethylene facilities in western Japan, with a decision expected in FY25.
Market Adaptation: The company is adapting to market shifts, such as the transition from acrylic to polyurethane lenses in China, where Mitsui Chemicals has a strong position.
Global Strategy: The company is strategically approaching different regions, leveraging its strengths in Europe, the Middle East, and South America while considering restructuring in other areas.


3296 JP:
Portfolio Reshuffling Strategy: The REIT plans to sell older, low-growth properties and acquire newer, high-growth, inflation-resistant properties to create a more resilient balance sheet.
Long-term Cash Flow Improvement: While portfolio reshuffling may lead to a near-term decline in NOI, it's expected to improve cash flow over the longer term through reinvestment of depreciation costs from newer property acquisitions.
Inflation Resilience: The REIT's strategy aims to create a balance sheet capable of generating cash flow that is resilient to inflation over the longer term.
Market Positioning: The REIT's fair-value yields are in line with the weighted averages for a broader set of REITs, suggesting it's competitively positioned in the market.



5076 JP:
Long-term Profit Growth Potential: While operating profits are expected to decline in FY25 due to one-time gains dropout, the company forecasts steady profit growth from FY26 onwards across multiple segments.
Diversified Growth Drivers: Expected profit increases in building construction, civil engineering, road civil engineering, and infrastructure management segments provide a balanced growth profile.
Infrastructure Management Segment Potential: Full-fledged profit growth in this segment is expected from FY28, with significant contributions from storage batteries and onshore wind projects.
Renewable Energy Focus: The company is investing heavily in wind power (¥400-500bn) and storage batteries (¥100-200bn) through the mid-2030s, positioning itself for long-term growth in renewable energy.
Stable Dividend Yield: The company offers a higher dividend yield compared to sector peers, with expectations of stable ¥60 per share dividends.
Attractive Valuation: The P/E looks low compared to the long-term profit growth potential, especially in the infrastructure management segment.
Strong Order Book: Plentiful work in hand supports expected sales growth in the civil engineering segment.
Margin Improvement: Expected improvements in gross margins, particularly in building construction and road civil engineering segments.
Strategic Project Development: The company is progressing with various projects, including the Aomori Sannohe-gun Power Storage Station, set to operate from August 2026.
Financial Flexibility: The company plans to fund investments through proceeds from sales of strategic shareholdings and project finance, indicating financial prudence.


8174 JP:
Steady Customer Growth: The company consistently adds 2,000-2,500 LPG customers per month on a net basis, with potential for increased growth through targeted marketing to high-usage customers like families.
M&A Potential: Large-scale M&A opportunities in the LPG sector could significantly boost customer numbers and sales volumes.
Cost Control: Curbs on SG&A costs, including customer acquisition costs, are expected to contribute to profit growth.
Consistent Profit Growth: Despite challenges in customer growth and LPG sales volumes, operating profits have maintained a growth trajectory, partly due to consistently high margins.
Strong Shareholder Returns: The company has a policy of a total return ratio of at least 100%, which includes dividends and share buybacks.
Dividend Growth: Forecasted DPS of ¥92.5 in FY25, increasing to ¥130 for both FY26 and FY27.
Share Buybacks: Planned buybacks of ¥6.0bn in FY25, ¥10.5bn in FY26, and ¥1.0bn in FY27.



8411 JP:
Strong Overall Performance: Profits attributable to owners of the parent rose 33% year-on-year, reaching 104% of full-year guidance. Consolidated net business profits up 15% year-on-year in Q1-3, reaching 82% of full-year guidance.
Equity-Related Income Growth: Significant increase from ¥80.0bn in H1 to ¥155.8bn in Q1-3.
Potential for Balance Sheet Improvement: The company may improve its balance sheet in Q4, possibly including booking losses on foreign bonds.
Strong Client-Facing Operations: Profit growth in client-facing operations accelerated in Q1-3, with improvements across all four client-facing segments.
Improved Lending Yield: In Japan (excluding government lending), the lending yield improved by 17bp year-on-year.
Improved NPL ratio (from 1.10% at end-September to 0.98% at end-December)


2579 JP:
Market Position: As a major bottler for a global brand, the company has significant market presence and brand power to support its pricing strategies.
Strong Cash Generation: The company's strong cash-generating power provides a foundation for potential increases in shareholder returns, including share buybacks.
Steady Earnings Trajectory: The company has shown steady earnings performance relative to guidance, indicating consistent execution of its business strategy.
Price Increase Strategy: The company's plan to implement price hikes for small and large PET bottle products demonstrates its ability to respond to inflationary pressures and protect margins.
Channel Performance: Strong sales in the high-margin convenience store channel, along with gained shelf space for core brands, suggest effective channel management.
Cost Savings Initiatives: Ongoing reforms are expected to deliver cost savings, contributing to profit growth.
Operational Efficiency: Ongoing reforms and cost-saving measures indicate a focus on improving operational efficiency.
Long-term Value Creation: The focus on ROE and P/B relationship for valuation indicates potential for long-term value creation.